US Patent

US11903942 — Compositions and use of varenicline for treating dry eye

Formulation · Assigned to Oyster Point Pharma Inc · Expires 2035-10-19 · 9y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods and pharmaceutical formulations for treating dry eye disease using varenicline.

USPTO Abstract

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Drugs covered by this patent

varenicline-tartrate (VARENICLINE TARTRATE)

Patent Metadata

Patent number: US11903942
Jurisdiction: US
Classification: Formulation
Expires: 2035-10-19
Drug substance claim: No
Drug product claim: Yes
Assignee: Oyster Point Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.